Treatment of heart failure with preserved ejection fraction with combination of western medicine and Yangyin Shuxin prescription: a single-center, single-blind, randomized, controlled clinical trial
- Conditions
- heart failure with preserved ejection fraction
- Registration Number
- ITMCTR2000003147
- Lead Sponsor
- The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
1. Symptoms±Signs of heart failure; LVEF>=45%; LVH/LAE/diastolic dysfunction
2. Aged 18 to 79 years;
3. NYHA classification I to III;
4. Sign the informed consent form.
1. ACS;
2. Aortic Dissection;
3. Fatal arrhythmia;
4. Acute Heart Failure;
5. Hypertension that cannot be controlled well;
6. Atrial fibrillation/Atrial flutter;
7. Advanced atrioventricular block;
8. Pericardial Diseases;
9. Valvular Disease;
10. Cardiomyopathy;
11. pulmonary embolism;
12. PAH;
13. Stroke in the past 3 months/Unfavorable unilateral limb movements due to Stroke;
14. Mental disease;
15. Moderate to severe anemia(HGB<90g/L);
16. Severe hepatic and renal dysfunction(ALT>3 times the normal upper limit, Cr>3mg/dl);
17. People with allergies or known to be allergic to this medicine and ingredients;
18. Disability in the lower limbs or inability to cooperate for various reasons;
19. Women who are preparing for pregnancy, childbearing or breastfeeding in the last 3 months;
20. Participated in other clinical trials in the past 3 months;
21. The survival period not exceeding 3 months;
22. Patients could not complete the study or could not comply with the requirements of the study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method GLS;UT;Peak VO2;LAVI;
- Secondary Outcome Measures
Name Time Method VEF;E/e';